For research use only. Not for therapeutic Use.
The compound is an ophthalmic corticosteroid, and categorized as an anti-inflammatory. Loteprednol Etabonate is the esther of Loteprednol. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Marketed by Bausch and Lomb as Lotemax in the U.S., ocular applications for this drug include the treatment of inflammation of the eye due to allergies, as well as chronic forms of keratitis, vernal keratoconjunctivitis, pingueculitis, and episcleritis.
| Catalog Number | A001102 |
| CAS Number | 82034-46-6 |
| Synonyms | NA |
| Molecular Formula | C24H31ClO7 |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | >17mg/mL in DMSO |
| Storage | 3 years -20C powder |
| Reference | </br>1:Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery. Salman İA.Eurasian J Med. 2016 Oct;48(3):186-188. doi: 10.5152/eurasianjmed.2016.0264. PMID: 28149143 Free PMC Article</br>2:Dose Uniformity of Topical Corticosteroids: A Simulated Trial of Fluorometholone Acetate 0.1% and Loteprednol Etabonate Gel 0.5. Stevens CE, Bennion JL, Caldwell MC, Townley JR, Apsey DA, Schwertner HA.J Ocul Pharmacol Ther. 2017 Mar;33(2):111-114. doi: 10.1089/jop.2016.0151. Epub 2017 Jan 31. PMID: 28140772 </br>3:Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. Liu RF, Wu XX, Wang X, Gao J, Zhou J, Zhao Q.Int Forum Allergy Rhinol. 2017 Apr;7(4):393-398. doi: 10.1002/alr.21882. Epub 2016 Nov 21. PMID: 27869354 Free PMC Article</br>4:Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N, Nakrani H, Raval M, Sheth N.Drug Deliv. 2016 Nov;23(9):3712-3723. Epub 2016 Sep 30. PMID: 27689408 </br>5:Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization. Sah AK, Suresh PK.Curr Drug Deliv. 2016 Aug 1. [Epub ahead of print] PMID: 27480117 </br>6:Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate. Soliman OAE, Mohamed EAM, El-Dahan MS, Khatera NAA.AAPS PharmSciTech. 2017 May;18(4):1228-1241. doi: 10.1208/s12249-016-0589-9. Epub 2016 Jul 28. PMID: 27469220 </br>7:PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study. Sah AK, Suresh PK, Verma VK.Artif Cells Nanomed Biotechnol. 2016 Jul 8:1-9. doi: 10.1080/21691401.2016.1203794. [Epub ahead of print] PMID: 27389068 </br>8:Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Sheppard JD, Comstock TL, Cavet ME.Adv Ther. 2016 Apr;33(4):532-52. doi: 10.1007/s12325-016-0315-8. Epub 2016 Mar 17. Review. PMID: 26984315 Free PMC Article</br>9:Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. Comstock TL, DeCory HH.Ocul Immunol Inflamm. 2017 Apr;25(2):267-274. doi: 10.3109/09273948.2015.1115879. Epub 2016 Jan 20. PMID: 26788833 </br>10:A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E.Clin Ophthalmol. 2015 Nov 6;9:2089-97. doi: 10.2147/OPTH.S94332. eCollection 2015. PMID: 26609219 Free PMC Article |
